CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells.
Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
SD-DC-BCMA 激活 T 细胞以进行抗原特异性肿瘤杀伤的能力，为过继性 T 细胞疗法在 MM 中的治疗应用提供了框架。
B细胞成熟抗原（BCMA）是多发性骨髓瘤（MM）过继性T细胞治疗的理想靶点。在本研究中，我们评估了表达BCMA的自分化单核细胞衍生树突状细胞（SD-DC-BCMA）激活T细胞以杀伤MM细胞的效果。
携带编码粒细胞-巨噬细胞集落刺激因子（GM-CSF）、白细胞介素-4（IL-4）和BCMA三顺反子cDNA的慢病毒修饰SD-DC-BCMA被生成。评估了由SD-DC-BCMA激活的T细胞对MM细胞的细胞毒性。
与未活化的T细胞或对照T细胞相比，经SD-DC-BCMA活化的T细胞对表达BCMA的MM细胞表现出剂量依赖性的细胞毒性，并产生高水平IFN-γ。在BCMA过表达细胞中，经SD-DC-BCMA活化的T细胞相比BCMA阴性细胞进一步显示出显著更高的杀伤能力。
Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated.
T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells.
The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
